Shopping Cart
- Remove All
- Your shopping cart is currently empty
Henatinib is an orally active small molecule multi-kinase inhibitor with broad antitumour effects. henatinib inhibits the activity of VEGFR-2 (IC50: 0.6 nM), c-kit (IC50: 3.3 nM), PDGFR (IC50: 41.5 nM). henatinib significantly inhibits VEGFR-2 phosphorylation and its downstream signalling pathways in human umbilical vein endothelial cells (HUVECs). Henatinib significantly inhibited VEGFR-2 phosphorylation and its downstream signaling pathway in human umbilical vein endothelial cells (HUVECs).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $2,140 | 8-10 weeks | |
50 mg | $2,785 | 8-10 weeks | |
100 mg | $3,520 | 8-10 weeks |
Description | Henatinib is an orally active small molecule multi-kinase inhibitor with broad antitumour effects. henatinib inhibits the activity of VEGFR-2 (IC50: 0.6 nM), c-kit (IC50: 3.3 nM), PDGFR (IC50: 41.5 nM). henatinib significantly inhibits VEGFR-2 phosphorylation and its downstream signalling pathways in human umbilical vein endothelial cells (HUVECs). Henatinib significantly inhibited VEGFR-2 phosphorylation and its downstream signaling pathway in human umbilical vein endothelial cells (HUVECs). |
Molecular Weight | 468.52 |
Formula | C25H29FN4O4 |
Cas No. | 1239269-51-2 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.